BioNTech's BNT113 missed progression-free survival in an HPV-linked head and neck cancer trial; study continues to test ...
In October 2026, BioNTech reported that its AHEAD-MERIT Phase 2/3 trial of mRNA cancer candidate BNT113 plus pembrolizumab in ...
When the coronavirus SARS-CoV-2 turned our world upside down, mRNA vaccines against COVID-19 brought a breakthrough. Their ...
Zacks Investment Research on MSN
MRNA stock gains over $4B in a week: Time to buy, hold or sell?
Shares of Moderna MRNA have gained more than 5% over the past week, adding roughly $4.2 billion in market value. The upside ...
Holding meds does not enhance humoral immunogenicity and is associated with disease flares for patients with inflammatory arthritis ...
An early data check showed the shot didn’t delay tumor progression in a form of head and neck cancer, though BioNTech is ...
Moderna Inc. (NASDAQ: MRNA) has delivered an extraordinary performance in 2026, transforming from a heavily scrutinized ...
Sean Hannity has alleged he was "pressured" to promote the COVID-19 vaccine, RadarOnline.com can report. Before Hannity ...
Why not prepare for COVID-19 while continuing treatment for your underlying condition? Every day, you manage your health ...
Moderna (MRNA) stock surged 14% after reports of a new NIH cancer research initiative and encouraging trial data with Merck.
Michael Mina, MD, PhD, explains LIBERTY trial findings on VYD2311 tolerability alone and given with an mRNA COVID-19 vaccine.
New EG95-based mRNA-lipid nanoparticle vaccines induced stronger and longer-lasting immunity against cystic echinococcosis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results